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Abstract
A progressive insulin resistant state develops throughout
human pregnancy. Inositol phosphoglycan P-type (P-
IPG), a second messenger of insulin, was reported to
negatively correlate with the degree of insulin resistance
in non-pregnant diabetic subjects. Urinary levels of P-IPG
were assessed in insulin resistant states during pregnan-
cy such as gestational diabetes mellitus (GDM, ns44)
and type 2 diabetes mellitus (type 2 DM, ns25) and in
69 normal pregnant women. Urinary levels of P-IPG were
higher in GDM than controls with a positive trend of
release throughout normal pregnancy (P-0.01). P-IPG
excretion was higher in diabetic (GDM and type 2 DM)
than in healthy women in the second trimester (P-0.05).
A higher P-IPG urinary excretion occurs during the sec-
ond trimester in pregnant women with clinically evident
insulin resistance with a positive association with poor
glycemic control.
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Inositol phosphoglycan P-type (P-IPG) was highly ex-
pressed in normal human pregnancy with a further
increase during preeclampsia w4, 5x, a complication of
pregnancy characterized by insulin resistance. P-IPG
belongs to a family of phospholipid-derived second mes-
sengers of insulin that can stimulate glucose and lipid
metabolism. These molecules seem to be involved in the
pathophysiology of insulin resistance w1x.
A case-control pilot study was carried out to assess
the role of P-IPG in clinically evident insulin resistant
states during pregnancy such as gestational diabetes
mellitus (GDM) and type 2 diabetes mellitus (type 2 DM).
This study was approved by the local Ethical Committee.
Forty-four women with GDM, 26 pregnant women with
type 2 DM (diagnoses made according to WHO criteria
w2x), and 69 normal pregnant women with similar mater-
nal age and gestational age were consecutively recruited
(Table 1). A mid-stream urine specimen was collected
once only from all women recruited for this study to
reduce any known bias. In fact, a higher excretion of P-
IPG was demonstrated well before the clinical onset of
preeclampsia w5x. P-IPG content of urinary specimens
was blindly assessed in triplicate using a polyclonal anti-
body-based ELISA as previously described w5x and cor-
rected for urinary creatinine. Power analysis indicated a
power of 0.96 with an alpha of 0.05 and a population
standard deviation of 0.1.
Maternal BMI and birth weights were higher on aver-
age in the type 2 DM group than controls (P-0.01). Fast-
ing plasma glucose was significantly higher in the GDM
and type 2 DM groups than in controls (5.9"1.1 and
6.6"1.5 vs. 5.1"0.9 mmol/L, respectively, P-0.01). The
urinary excretion of P-IPG was higher in women with
GDM and type 2 DM compared with controls (Table 1;
P-0.01). A positive trend in P-IPG excretion throughout
pregnancy was found in the control group only (rs0.51,
P-0.01). No association was found with 2 h postprandial
glycemia. A higher release of P-IPG was found in diabetic
subjects before 30 weeks’ gestation compared to normal
pregnancy (Figure 1), whereas the difference was lost in
the third trimester, when insulin resistance is physiologi-
cally increased.
The development of a physiological insulin resistant
state during pregnancy is considered to be a mechanism
that allows a safe nutrient balance between the mother
and the fetus. When this metabolic balance is disrupted,
when a decreased maternal insulin sensitivity or incre-
ased insulin resistance exists, abnormalities of glucose
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Table 1 Patient characteristics, glycemic control, and pregnancy outcome (mean"SD) in gestational diabetes mellitus (GDM), type
2 diabetes mellitus (type 2 DM), and control groups. In the second part of the table is reported P-IPG urinary excretion in the three
study groups and its correlation with clinical parameters.
GDM (ns44) Type 2 DM (ns25) Controls (ns69)
Maternal age (years) 33.3"4.7 32.9"4.5 33.6"5.4
Pre-pregnancy BMI (kg/m2) 23.2"3.0 24.6"3.2* 22.2"2.8
Nulliparous (n) 18 (40.9%) 13 (52.0%) 26 (37.7%)
Ethnicity (Caucasian/other; n) 29/15 11/14 40/29
Smoking (n) 31 11 35
Gestational age (weeks) 30.6"6.5 31.0"5.9 30.7"6.0
Glycemic control
Fasting plasma glucose (mmol/L) 6.3"0.7* 6.6"1.5* 5.1"0.9
Post-prandial glycemia (mmol/L) 7.1"0.4 7.3"0.9 –
HbA1c (%) 6.2"0.6 6.6"0.8 –
Gestational age at delivery (weeks) 38.5"1.4 38.3"1.7 38.9"1.5
Birth-weight (g) 3290"392 3503"376* 3211"333
P-IPG urinary excretion
Mean (% of positive control) 33.1 49.8*,** 27.5
Median (% of positive control) 27.7 51.8 25.1
SEM (% of positive control) 1.9 3.2 1.2
Range (% of positive control) 19.7–64.2 5.6–76.0 5.6–59.9
Correlations
Gestational age rs–0.21 rs–0.54 rs0.51
Ps0.17 P-0.01 P-0.01
Pre-pregnancy BMI rs–0.04 rs0.10 rs–0.15
Ps0.77 Ps0.59 Ps0.40
Fasting plasma glucose rs–0.02 rs–0.28 rs–0.18
Ps0.89 Ps0.18 Ps0.77
Post-prandial glycemia rs0.25 rs0.21 –
Ps0.09 Ps0.38
HbA1c rs0.23 rs0.22 –
Ps0.13 Ps0.36
Birth-weight rs–0.14 rs–0.36 rs0.20
Ps0.36 Ps0.13 Ps0.43
*P-0.01, compared with controls.
**P-0.01, type 2 diabetes mellitus (type 2 DM) vs. gestational diabetes mellitus (GDM).
Figure 1 P-IPG urinary excretion in the three study groups stratified by gestational age (Cscontrols, GDMsgestational diabetes
mellitus, type 2 DMstype 2 diabetes mellitus). Values were divided into 5-week spans and reported as mean and standard error. P-
IPG release was higher in GDM and type 2 DM groups between 21 and 30 weeks of gestation compared with controls (*P-0.05;
**P-0.01).
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metabolism become clinically evident (GDM or type 2
DM). The role of molecules with insulin-like characteris-
tics stimulated the interest of many researchers. In dia-
betic subjects, a reduced P-IPG content in muscle-
biopsy and urinary specimens from insulin-resistant sub-
jects was reported w1x, suggesting that P-IPG has an
important role in mediating the effects of insulin on
peripheral glucose utilization.
Interestingly, we found a higher production/release of
P-IPG in the second trimester in women with glucose
tolerance abnormalities (GDM and type 2 DM) compared
to healthy women. The comparison to non-pregnant
insulin-resistant subjects seems to support the hypoth-
esis of the fetal/placental unit as a potential source of P-
IPG w4x which might partially restore insulin sensitivity
and glucose disposal. In fact, Nestler and co-workers w3x
reported that administration of chiro-inositol (P-IPG)
increases insulin sensitivity in women with polycystic
ovary syndrome, a disorder strongly associated with
insulin resistance. The anabolic effect of P-IPG may
explain the increased body fat and birth weight in fetuses
from diabetic mothers compared to fetuses from normal
pregnancies. Therefore, the fetal/placental unit seems
not to have a simply permissive role in pregnancies with
abnormal glucose metabolism; rather it adapts to the
maternal environment and assumes an active role.
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